The treatment landscape for acromegaly, a rare and burdensome hormonal disorder, has significantly expanded with the approval of a growth hormone receptor antagonist, multiple somatostatin receptor ligands (SRLs), and several late-stage emerging therapies. In this first of two enduring podcasts from a live satellite symposium held in conjunction with the Pituitary Society’s 2024 Biennial Membership Forum, three experts provide a succinct overview of acromegaly, discussing its pathophysiology, multisystemic manifestations, and burden, as well as an in-depth review of current and emerging treatments and the latest evidence supporting their use. Don’t miss the opportunity to stream the podcast video or the audio-only version and gain access to downloadable evidence and a shared decision-making guide to reference in your daily practice.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/podcast/examining-pathophysiology-burden-evolving-treatment-landscape-acromegaly
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Recordati Rare Disease Inc. - Amount: 133166.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Endocrinology, Diabetes, and Metabolism